The majority of surface receptors belong to the Eph receptor tyrosine kinase (RTK) family, which is divided into EphA and EphB subclasses based on sequence homology and preferential binding to ephrin-A and ephrin-B ligands, respectively.
Ephrin-A and Ephrin-B ligands, as well as nine EphA (EphA1-8,10) and five EphB (EphB1-4,6) receptors, are expressed in humans. Eph receptors interact with ligands that are frequently membrane-bound, which makes them different from most RTKs and enables both "forward signaling" in the receptor-bound cell and "reverse signaling" in the ephrin-bound cell. Eph receptors can signal in the absence of ligand binding and kinase activation in addition to "forward signaling" by interacting with other RTKs, such as HER2.
In order to control migration and cell adhesion during development, eph receptor tyrosine kinases and their ligands, the ephrins, have a major impact on cell fate, morphogenesis, and organogenesis. Ephrins and numerous Eph receptors have now also been discovered to play significant roles in the development of cancer. Consequently, it is thought that the Eph/ephrin system represents a promising therapeutic target.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V105330 | UniPR500 | 2085767-98-0 | UniPR500, a derivative of UniPR129, is a competitive EphA2 receptor antagonist with a Ki of 0.78 μM. |
|
V69445 | UniPR505 | 2938227-14-4 | UniPR505 (Compound 14) is an EphA2 antagonist (inhibitor) with IC50 of 0.95 µM. |
|
V69444 | Urolithin D | 131086-98-1 | Urolithin D is a competitive and reversible antagonist of the EphA receptor. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
